Bobeica Carmen, Rebegea Laura, Murariu Gabriel, Dobre Michaela, Nechita Aurel, Tatu Alin Laurentiu, Niculet Elena, Anghel Lucretia, Fotea Silvia, Craescu Mihaela
Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, 'Dunarea de Jos' University, 800010 Galati, Romania.
Clinical Medical Department, Faculty of Medicine and Pharmacy, 'Dunarea de Jos' University, 800010 Galati, Romania.
Exp Ther Med. 2022 Jan;23(1):15. doi: 10.3892/etm.2021.10937. Epub 2021 Oct 29.
Lung cancer is the main cause of oncological death in the US and worldwide, constituting a significant public health problem. The incidence of lung cancer is on the increase. In the present study, the diagnostic process was carried out and treatment options were considered to determine the therapeutic response of a patient diagnosed with lung cancer. The case of an early stage lung cancer patient who benefited from surgical treatment was presented. The pathology report stated the complete diagnosis to be pleomorphic lung cancer with an adenocarcinoma component, pT2aN0M0, with focal positivity for thyroid transcription factor 1 (TTF1), without epidermal growth factor receptor (EGFR) mutations and ALK recombinations, having an initial clinical stage of IB and programmed death ligand-1 (PD-L1) positivity with a tumor proportion score of over 70%. The patient underwent radiotherapy treatment and was administered osteoclast inhibitors and immunotherapy, with no favorable therapeutic effect and with the presence of secondary cutaneous adverse effects to pembrolizumab. As a main cause of death, lung cancer registers a low general survival rate even in patients with targeted therapies or immunotherapy. By better identifying the patients at risk, one can establish a more efficient personalized treatment; the future objective of scientific studies is the follow-up of adverse effects of new therapies.
肺癌是美国乃至全球肿瘤死亡的主要原因，构成了一个重大的公共卫生问题。肺癌的发病率正在上升。在本研究中，开展了诊断过程并考虑了治疗方案，以确定一名被诊断为肺癌患者的治疗反应。本文介绍了一名受益于手术治疗的早期肺癌患者的病例。病理报告显示完整诊断为具有腺癌成分的多形性肺癌，pT2aN0M0，甲状腺转录因子1（TTF1）呈局灶阳性，无表皮生长因子受体（EGFR）突变和ALK重排，初始临床分期为IB期，程序性死亡配体-1（PD-L1）阳性，肿瘤比例评分超过70%。该患者接受了放射治疗，并给予了破骨细胞抑制剂和免疫治疗，但治疗效果不佳，且出现了帕博利珠单抗的继发性皮肤不良反应。作为主要死亡原因，即使是接受靶向治疗或免疫治疗的肺癌患者总体生存率也较低。通过更好地识别高危患者，可以制定更有效的个性化治疗方案；科学研究的未来目标是跟踪新疗法的不良反应。
